Figure 1.

Treatment with anti-α₁ mAb prevents DSS-mediated colitis. Mice were fed DSS over 7 days and treated with mAb (control or anti-α₁) every second day starting at day 0. Disease severity was measured daily and is expressed in terms of (a) body weight, (b) fecal blood, (c) diarrhea, and (d) disease activity index (combined index of a + b + c). The isotype mAb-treated group exhibited no significant differences from WT mice receiving DSS alone (see Figure 2). *P < 0.05; anti-α₁ mAb vs. isotype mAb. Data represent mean ± SEM.